company background image
3D0A logo

Telo Genomics DB:3D0A Stock Report

Last Price

€0.051

Market Cap

€5.7m

7D

-18.4%

1Y

-38.6%

Updated

26 Dec, 2024

Data

Company Financials

Telo Genomics Corp.

DB:3D0A Stock Report

Market Cap: €5.7m

3D0A Stock Overview

A molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions primarily in Canada. More details

3D0A fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap (€9M)

Makes less than USD$1m in revenue (CA$0)

Earnings have declined by 26% per year over past 5 years

Highly volatile share price over the past 3 months compared to the German market

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Telo Genomics Corp. Competitors

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€15.2m

4SC

DB:VSC

€41.6m

bioXXmed

XTRA:T5O

€673.0k

Price History & Performance

Summary of share price highs, lows and changes for Telo Genomics
Historical stock prices
Current Share PriceCA$0.051
52 Week HighCA$0.13
52 Week LowCA$0.025
Beta0.97
1 Month Change67.21%
3 Month Change-23.88%
1 Year Change-38.55%
3 Year Change-82.29%
5 Year Change-71.02%
Change since IPO-97.19%

Recent News & Updates

Recent updates

Shareholder Returns

3D0ADE BiotechsDE Market
7D-18.4%1.2%-0.3%
1Y-38.6%-14.3%7.0%

Return vs Industry: 3D0A underperformed the German Biotechs industry which returned -14.3% over the past year.

Return vs Market: 3D0A underperformed the German Market which returned 7% over the past year.

Price Volatility

Is 3D0A's price volatile compared to industry and market?
3D0A volatility
3D0A Average Weekly Movement87.6%
Biotechs Industry Average Movement7.0%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 3D0A's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 3D0A's weekly volatility has increased from 54% to 88% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aSabine Maiwww.telodx.com

Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions primarily in Canada. Its TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability to identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with high risk of transition to multiple myeloma (MM). The company also develops TeloView NDMM that predicts newly diagnosed MM patients who may relapse on 1st line therapy; TeloMRD-D Enumaeration that identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD detected cells in post-transplant patients.

Telo Genomics Corp. Fundamentals Summary

How do Telo Genomics's earnings and revenue compare to its market cap?
3D0A fundamental statistics
Market cap€5.74m
Earnings (TTM)-€1.73m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.3x

P/E Ratio

Is 3D0A overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3D0A income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$2.59m
Earnings-CA$2.59m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.035
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 3D0A perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 07:59
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Telo Genomics Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution